A number of other equities analysts have also recently weighed in on JNCE. Robert W. Baird reissued an outperform rating and set a $30.00 price objective on shares of Jounce Therapeutics in a report on Monday, September 18th. Zacks Investment Research raised Jounce Therapeutics from a hold rating to a buy rating and set a $13.00 price objective on the stock in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Jounce Therapeutics currently has an average rating of Buy and an average target price of $23.67.
Shares of Jounce Therapeutics (NASDAQ JNCE) traded up $0.04 during midday trading on Monday, hitting $14.81. The company had a trading volume of 130,200 shares, compared to its average volume of 158,505. Jounce Therapeutics has a 52 week low of $11.05 and a 52 week high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to analysts’ expectations of $20.00 million. Jounce Therapeutics’s revenue for the quarter was up 7.1% on a year-over-year basis. research analysts anticipate that Jounce Therapeutics will post -0.73 earnings per share for the current year.
WARNING: “Jounce Therapeutics, Inc. (JNCE) Given a $28.00 Price Target at J P Morgan Chase & Co” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/14/jounce-therapeutics-inc-jnce-given-a-28-00-price-target-at-j-p-morgan-chase-co.html.
Institutional investors have recently made changes to their positions in the business. Macquarie Group Ltd. purchased a new position in Jounce Therapeutics in the 3rd quarter worth approximately $124,000. American International Group Inc. increased its stake in Jounce Therapeutics by 132.2% in the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after purchasing an additional 5,442 shares during the period. Teachers Advisors LLC increased its stake in Jounce Therapeutics by 26.4% in the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares during the period. Ark Investment Management LLC increased its stake in Jounce Therapeutics by 558.9% in the 2nd quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after purchasing an additional 10,121 shares during the period. Finally, Nationwide Fund Advisors increased its stake in Jounce Therapeutics by 203.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after purchasing an additional 8,007 shares during the period. 44.47% of the stock is currently owned by institutional investors and hedge funds.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.